Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22737698 | 0.89 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL38660895 | 0.87 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL20365049 | 0.84 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL2475741 | 0.84 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL3278728 | 0.84 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL22783955 | 0.84 | HTR6 (0.60) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL29082713 | 0.82 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL7814587 | 0.82 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL3810047 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL22607680 | 0.79 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HTR6 1527/4885L3MBTL3 3804/4885L3MBTL1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.